A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
Objective: Agomelatine is a new mechanism of antidepressants, which is approved by Taiwan Food and Drug Administration and available in Taiwan.Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. The structuresof agomelatine are similar to melatonin with not only the effects to maintain depression symptoms but also can help patients who have insomnia.Methods: This is a retrospective study. In a mental hospital indoi:10.22159/ijap.2021.v13s1.y0110 fatcat:mxm4ws7yhvbw3kul66rkxox2om